Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?

Practical Pharmacological Treatment of Heart Failure: Does Ejection Fraction Matter Anymore?

Heart failure (HF) is a complex clinical syndrome involving structural and/or functional abnormalities of the heart. Heart failure is often classified based on left ventricular ejection fraction, which serves as a predictor of mortality. The majority of the data supporting disease-modifying pharmaco...

Full description

Bibliographic Details
Main Authors:	Jonathan C. H. Chan, Emily Cowley, Michael Chan
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	Journal of Cardiovascular Development and Disease
Subjects:	heart failure ejection fraction SGLT2i beta blocker spironolactone ivabradine
Online Access:	https://www.mdpi.com/2308-3425/10/3/114

Similar Items

The mortality benefit of carvedilol versus bisoprolol in patients with heart failure with reduced ejection fraction
by: Ki Hong Choi, et al.
Published: (2019-09-01)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
by: Hui‐min Zhou, et al.
Published: (2023-02-01)

Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?
by: V. D. Zakiev, et al.
Published: (2023-12-01)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
by: Tetsuro Tsujimoto, et al.
Published: (2020-12-01)

Plasma Biomarker Profiling in Heart Failure Patients with Preserved Ejection Fraction before and after Spironolactone Treatment: Results from the Aldo-DHF Trial
by: Moritz Schnelle, et al.
Published: (2021-10-01)

Myocardial strain to identify benefit from beta‐blockers in patients with heart failure with reduced ejection fraction
by: Chan Soon Park, et al.
Published: (2022-04-01)

Treatment response to spironolactone in patients with heart failure with preserved ejection fraction: a machine learning-based analysis of two randomized controlled trialsResearch in context
by: Karl-Patrik Kresoja, et al.
Published: (2023-10-01)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
by: Manting Choy, et al.
Published: (2022-08-01)

Heart failure with preserved ejection fraction in elderly. From pathophysiology to treatment: an unresolved problem
by: Matteo Beltrami, et al.
Published: (2019-05-01)

Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction
by: Krittayaphong R, et al.
Published: (2019-12-01)

Spironolactone Reduces the Risk of Death in Veterans With Heart Failure With Preserved Ejection Fraction
by: Katherine E. Kurgansky, et al.
Published: (2024-07-01)

Beta Blockers Up-Titration in Patients with Heart Failure Reduced Ejection Fraction and Cardiac Resynchronization Therapy, a Single Center Study
by: Daniele Masarone, et al.
Published: (2019-06-01)

Differing effects of beta-blockers on long-term clinical outcomes following percutaneous coronary intervention between patients with mid-range and reduced left ventricular ejection fraction
by: Jun Shitara, et al.
Published: (2021-01-01)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
by: Sho Suzuki, et al.
Published: (2020-10-01)

The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction
by: Daniele Masarone, et al.
Published: (2021-08-01)

Beneficial effects of ivabradine in patients with heart failure, low ejection fraction, and heart rate above 77 b.p.m.
by: Nadia Bouabdallaoui, et al.
Published: (2019-12-01)

SGLT2 inhibitors in heart failure with reduced ejection fraction
by: Uday Sankar Das, et al.
Published: (2021-10-01)

IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
by: Yu. M. Lopatin
Published: (2012-08-01)

Beta-blockers are associated with reverse remodeling in patients with dilated cardiomyopathy and mid-range ejection fraction
by: Nobuyuki Enzan, et al.
Published: (2021-11-01)

Eligibility of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction: Insights from the Colombian heart failure registry (RECOLFACA)
by: Juan Esteban Gómez-Mesa, et al.
Published: (2024-08-01)

Heart failure with preserved ejection fraction and atrial fibrillation: recent advances and open questions
by: Laurent Fauchier, et al.
Published: (2023-02-01)

Titration of medications and outcomes in multi‐ethnic heart failure cohorts (with reduced ejection fraction) from Singapore and New Zealand
by: Tiew‐Hwa Katherine Teng, et al.
Published: (2023-04-01)

The effect of beta-blockers in acute heart failure according to heart rate
by: Hyun-Jin Kim, et al.
Published: (2021-07-01)

Short-term/long-term prognosis with or without beta-blockers in patients without heart failure and with preserved ejection fraction after acute myocardial infarction: a multicenter retrospective cohort study
by: Xue-song Wen, et al.
Published: (2022-04-01)

Outcomes of Spironolactone Withdrawal in Dilated Cardiomyopathy With Improved Ejection Fraction
by: Yanjia Chen, et al.
Published: (2021-09-01)

Effects of SGLT2 inhibitor dapagliflozin in patients with heart failure with reduced ejection fraction
by: N. R. Khasanov
Published: (2020-09-01)

Aggressive beta-blocker titration in stabilized acute heart failure patients with low left ventricular ejection fraction
by: Yoga Waranugraha, MD, et al.
Published: (2021-08-01)

The role of heart rate and ivabradine in acute heart failure
by: Edoardo Sciatti, et al.
Published: (2019-10-01)

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
by: Andrea Beatriz De Lorenzi, et al.
Published: (2023-01-01)

Damage to the Cardiovascular System in Patients with SARS-CoV-2 Coronavirus Infection. Part 1: Predictors of the Development of an Unfavorable Prognosis
by: V. I. Podzolkov, et al.
Published: (2022-01-01)

Pharmacological therapy, slows the heart rate, in patientswith hypertension and chronic heart failure: theory and application in clinical practice
by: A I Ponomareva, et al.
Published: (2016-03-01)

Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
by: Eduard Shantsila, et al.
Published: (2020-07-01)

Heart failure with preserved ejection fraction in patients with type 2 diabetes mellitus: pathophysiology and treatment options
by: A. A. Borisov, et al.
Published: (2021-07-01)

Effects of renin-angiotensin system inhibitor and beta-blocker use on mortality in older patients with heart failure with reduced ejection fraction in Japan
by: Kei Kawada, et al.
Published: (2024-05-01)

Use of angiotensin receptor blocker is associated with improved 1 year mortality in heart failure with mid‐range ejection fraction
by: Bin Wang, et al.
Published: (2021-04-01)

NEW OPPORTUNITIES IN TREATMENT OF CHRONIC HEART FAILURE WITH NORMAL EJECTION FRACTION
by: A. G. Dushina, et al.
Published: (2015-08-01)

Novel Medical Treatments and Devices for the Management of Heart Failure with Reduced Ejection Fraction
by: Michele Alfieri, et al.
Published: (2024-04-01)

Dynamic trajectories of left ventricular ejection fraction in heart failure with improved ejection fraction
by: Yang Jiang, et al.
Published: (2024-11-01)

Heart Failure With Midrange Ejection Fraction: Prior Left Ventricular Ejection Fraction and Prognosis
by: Xinxin Zhang, et al.
Published: (2021-08-01)

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
by: Andrew J.S. Coats, et al.
Published: (2024-02-01)